Skip to content
Search

Latest Stories

Nine new medicines added to ‘DND’ list

Nine more new products have been classed as ‘Drugs for which Discount is Not Deducted’ (DND list) from 1 July 2022, announced Department of Health and Social Care (DHSC).

This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating Committee.


The Committee had made an application to DHSC and NHSBSA for the following  9 products to be added to the DND list of Individual items to which the discount deduction scale will no longer apply from July 2022:

  • Fludrocortisone 50micrograms/5ml oral suspension (Group)
  • Lorazepam 1mg/5ml oral suspension (Group)
  • Lorazepam 500micrograms/5ml oral suspension (Group)
  • Zopiclone 3.75mg/5ml oral solution (Group)
  • Zopiclone 7.5mg/5ml oral solution (Group)
  • GA explore5 oral powder 12.5g sachets
  • HCU explore5 oral powder 12.5g sachets
  • MSUD explore5 oral powder 12.5g sachets
  • TYR explore5 oral powder 12.5g sachets

The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.

Any items covered by the ‘Group Items’ heading are not listed again individually in Part II. Contractors can also check the Actual Medicinal Product (AMP) listing on Dictionary of Medicines and Devices (dm+d) to identify whether a product meets the DND criteria.

Group items

Any products that are covered by one or more of the Group items categories below are reimbursed without any discount deduction applied.

  • Cold Chain Storage (ALL)
  • Schedule 1, 2 or 3 Controlled Drugs: Products containing drugs listed in Schedules 1, 2 and 3 of the Misuse of Drugs Regulation 2001
  • Cytotoxic or Cytostatic item (ALL):
  • Immunoglobulins (ALL)
  • Insulins for injection (ALL)
  • Vaccines and antisera (ALL)
  • Unlicensed medicines: ‘Specials’ not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate)
  • Hazardous chemicals

Individual items 

Products that do not are covered by one or more of the Group item categories above must fulfil all three of the following criteria to qualify for entry to the DND list.

  • the manufacturer(s), AAH and Alliance do not offer pharmacy contractors a discount
  • fewer than 500,000 items per year are dispensed of the product
  • average net ingredient cost (NIC) per item is more than £50

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less